The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC 50 and MIC 90 values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 g/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.
The increasing incidence of invasive infections caused by multidrug-resistant staphylococcal isolates has caused significant clinical concern. Newer antibiotics, such as linezolid, are alternatives in the treatment of severe infections caused by multidrug-resistant staphylococci. In the last few years, linezolid-resistant staphylococci, mainly in patients undergoing prolonged therapy, have been reported (4, 5, 13) . The most common mechanism of linezolid resistance involves mutations in the 23S rRNA gene. The presence of cfr, a plasmid-borne gene that encodes a 23S rRNA methyltransferase in some linezolid-resistant staphylococcal isolates, has been described (14, 19) , and an outbreak of cfr-positive methicillin-resistant Staphylococcus aureus (MRSA) in a Spanish hospital was recently reported (3, 15) . Furthermore, mutations in ribosomal proteins L3 and L4 have been associated with resistance to oxazolidinones (11, 12) .
TR-700 (torezolid) is the active moiety of the prodrug TR-701 (torezolid phosphate), a new oxazolidinone with potent activity against Gram-positive bacteria. Schaadt et al. (17) demonstrated that TR-700 was more active against staphylococci and enterococci than linezolid. In addition, for MRSA and methicillin-susceptible S. aureus (MSSA), the spontaneous mutation frequency was 16-fold lower for TR-700 than for linezolid (12) . TR-700 presents a better pharmacokinetic profile than linezolid; its mean half-life of 8 to 11.1 h is approximately 2-fold longer, thus allowing once-daily dosing (16) .
The in vitro activity of TR-700 was evaluated against a collection of staphylococcal blood isolates. The strains were obtained as part of a multicenter program for surveillance of antimicrobial resistance, the Vigilancia de Resistencias a los Antimicrobianos (VIRA) study.
( (2) . Etest strips (AB Biodisk, Solna, Sweden) were used to confirm linezolid MICs of Ͼ4 g/ml. The presence of the cfr gene in the 12 linezolid-nonsusceptible strains was investigated using PCR with specific primers as described elsewhere (9) . The presence of the 746-bp amplified cfr gene fragment was assessed by agarose gel electrophoresis. Table 1 summarizes the MIC results for TR-700 and the comparator agents tested against the 660 staphylococcal blood isolates. The MIC 50 and MIC 90 values for TR-700 against the linezolid-susceptible MRSA isolates were 0.25 and 0.5 g/ml, respectively. Against the MSSA and the linezolid-susceptible CoNS isolates, these values were both 0.25 g/ml. Based on the MIC 90 values, TR-700 was 4-fold to 8-fold more active than linezolid against linezolid-susceptible staphylococci and 2-fold to 4-fold more active than vancomycin. Against MRSA, the MIC 90 values of TR-700, daptomycin, vancomycin, and linezolid were 0.5, 0.5, 2, and 4 g/ml, respectively. Among the MRCoNS, the MIC 90 values (g/ml) were 0.25 for TR-700, 0.5 for daptomycin, 2 for both linezolid and vancomycin, and 8 for teicoplanin.
Twelve isolates were not susceptible to linezolid (seven MRSA and five MRCoNS). The seven MRSA isolates with linezolid MICs of 16 g/ml showed TR-700 MICs of 0.5 g/ml. These isolates were susceptible to daptomycin, vancomycin, and teicoplanin. For the five linezolid-resistant (MICs of 16 to 256 g/ml) MRCoNS (two S. epidermidis, two S. hominis, and one S. haemolyticus) isolates, the MICs of TR-700 were 0.25 to 4 g/ml. These five isolates were inhibited at daptomycin and vancomycin MICs of 0.5 and 2 g/ml, respectively. One of the five linezolid-resistant CoNS was nonsusceptible to teicoplanin. The two MRSA isolates with vancomycin MICs of 4 g/ml and the five teicoplanin-resistant MRCoNS isolates were inhibited by TR-700 at 0.25 to 0.5 g/ml. Table 2 shows the distribution of the TR-700 and linezolid MICs for the organisms tested. All the S. aureus and linezolid-susceptible CoNS tested were inhibited by 0.5 g/ml of TR-700. Linezolid inhibited these isolates at 4 g/ml.
Two MRCoNS isolates (one S. epidermidis and one S. homi- In the present study, TR-700 exhibited excellent activity against the staphylococcal bloodstream isolates tested. With the exception of 4 of 660 strains (0.6%), all isolates were inhibited by 0.5 g/ml of TR-700. The detection of cfr-mediated resistance among staphylococcal clinical isolates is a cause for concern because of the potential for rapid transmission between species. We detected the cfr gene in three different staphylococcal species (S. aureus, S. hominis, and S. epidermidis) collected in 2006 from different Spanish hospitals. In 2008, an outbreak of linezolid-resistant S. aureus was reported at Hospital Clínico San Carlos, Madrid, Spain (15) . Five cfrpositive MRSA isolates obtained from blood during the outbreak were included in this study. A cfr-positive S. hominis isolate was also collected in 2006 in the same hospital. These data indicate the need for continued monitoring of susceptibility. Global surveillance studies show that linezolid resistance remains rare, particularly among S. aureus strains (6, 8) . TR-700 was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested. The results of our study agree with those of other authors (7, 10, 17, 18) and confirm the greater in vitro potency of TR-700 over linezolid against staphylococci, including linezolid-resistant and vancomycinnonsusceptible strains. Further clinical evaluations are warranted to confirm the efficacy of this agent. 
